Healthy fundamentals are intact
25/08/21 -"Our target price is a beneficiary of both near-term tailwinds and solid longer-term fundamentals. While our near-term earnings benefit on the back of the strong H1 recovery, upward revisions to both ..."
Pages
54
Language
English
Published on
25/08/21
You may also be interested by these reports :
10/05/24
Novonesis reported largely in-line Q1 24 numbers. Q1 24 revenue was up 45% on a pro-forma basis, helped by strong performances in the key segments of ...
08/05/24
Sandoz is moving ahead well with two crucial aspects of its medium-term sales and profitability goals: 1/ a strong performance from Biosimilars and ...
07/05/24
Q1 sales missed the consensus estimates, although the CER growth was largely in line with the firm’s full-year outlook. Biosimilars were the main ...
03/05/24
Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the ...